Plasma soluble gp130 levels are increased in older subjects with metabolic syndrome. The role of insulin resistance

Atherosclerosis

Volumn 213, Issue 1, 2010, Pages 319-324

  Zuliani, Giovanni ^a   Galvani, Matteo ^a   Maggio, Marcello ^b   Volpato, Stefano ^a   Bandinelli, Stefania ^c   Corsi, Anna Maria ^d   Lauretani, Fulvio ^e   Cherubini, Antonio ^f   Guralnik, Jack M ^g   Fellin, Renato ^a   Ferrucci, Luigi ^d,g  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

^c Azienda Sanitaria di Firenze   (Italy)

^d Tuscany Regional Health Agency   (Italy)

^e UNIVERSITY HOSPITAL OF PARMA   (Italy)

^f UNIVERSITY OF PERUGIA   (Italy)

^g NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

Interleukin 6; Metabolic syndrome; Pathway; Sgp130; Trans Signalling

Indexed keywords

GLYCOPROTEIN GP 130; INSULIN; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR;

ADULT; AGED; AGING; ARTICLE; BLOOD LEVEL; DIABETES MELLITUS; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PLASMA; PRIORITY JOURNAL;

AGED; AGING; CYTOKINE RECEPTOR GP130; DIET; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; INSULIN RESISTANCE; INTERLEUKIN-6; MALE; METABOLIC SYNDROME X; RECEPTORS, INTERLEUKIN-6; SIGNAL TRANSDUCTION;

EID: 77958478644     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.08.074     Document Type: Article

References (29)

1. Reaven G.M. Banting lecture 1988: role of insulin resistance in human disease. Diabetes 1988, 37:1595-1607.
2. Ferrannini E., Haffner S.M., Mitchell B.D., Stern M.P. Hyperinsulinaemia: the key feature of a cardiovascular and metabolic syndrome. Diabetologia 1991, 34:416-422.
3. Pickup J.C., Mattock M.B., Chusney G.D., et al. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 1997, 40:1286-1292.
4. Yudkin J.S., Stehouwer C.D.A., Emeis J.J., et al. C-reactive protein in healthy subjects: association with obesity, insulin resistance, and endothelial dysfunction. Arterioscler Thromb Vasc Biol 1999, 19:972-978.
5. Festa A., D'Agostino R., Howard G., Mykkanen L., Tracy R.P., Haffner S.M. Chronic subclinical inflammation as part of the insulin resistance syndrome: the insulin resistance atherosclerosis study (IRAS). Circulation 2000, 102:42-47.
6. Hak A.E., Pols H.A., Stehouwer C.D., et al. Markers of inflammation and cellular adhesion molecules in relation to insulin resistance in nondiabetic subjects. J Clin Endocrinol Metabol 1991, 86:4398-4405.
7. Zuliani G., Volpato S., Galvani M., et al. Elevated C-reactive protein levels and metabolic syndrome in the elderly: the role of central obesity. Data from the InChianti study. Atherosclerosis 2009, 203:626-632.
8. Despres J.-P., Prud'homme D., Pouliot M.C., Tremblay A., Bouchard C. Estimation of deep abdominal adipose tissue accumulation from simple anthropometric measurements in men. Am J Clin Nutr 1991, 54:471-477.
9. Maggio M., Guralnik J.M., Longo D.L., Ferrucci L. Interleukin-6 in aging and chronic disease: a magnificent pathway. J Geront Med Sci 2006, 61A:575-584.
10. Jones S.A., Horiuchi S., Topley N., Yamamoto N., Fuller G.M. The soluble interleukin 6 receptor: mechanisms of production and implications in disease. FASEB J 2001, 15:43-58.
11. Hurst S.M., Wilkinson T.S., McLoughlin R.M., et al. IL-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity 2001, 14:705-714.
12. Ferrucci L., Bandinelli S., Benvenuti E., et al. Subsystems contributing to the decline in ability to walk: bridging the gap between epidemiology and geriatric practice in the InCHIANTI study. J Am Geriatr Soc 2000, 48:1618-1625.
13. Grundy S.M., Cleeman J.I., Daniels S.R., et al. Diagnosis and management of metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 2005, 112:2735-2752.
14. Jostock T., Mullberg J., Ozbek S., et al. Soluble gp130 in the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. Eur J Biochem 2001, 268:160-167.
15. Hung J., McQuillan B.M., Chapman C.M.L., Thompson P.L., Beilby J.P. Elevated interleukin 18 levels are associated with the metabolic syndrome independent of obesity and insulin resistance. Arterioscler Thromb Vasc Biol 2005, 25:1268-1273.
16. Jablonska E., Jablonski J. Effect of IL-18 on the release of IL-6 and its soluble receptors: sIL-6r and sgp130 by human neutrophils. Immunol Invest 2002, 31:159-167.
17. Jablonska E., Marcinczyk M. Role of interleukin-15 and interleukin-18 in the secretion of sIL6r and sgp130 by human neutrophils. Mediat Inflamm 2003, 12:179-183.
18. Tilg H., Trehu E., Atkins M.B., Dinarello C.A., Mier J.W. Interleukin-6 as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood 1994, 83:113-118.
19. Bastard J.-P., Jardel C., Delattre J., Hainque B., Bruckert E., Oberlin F. Evidence for a link between adipose tissue IL-6 content and serum C-reactive protein concentrations in obese subjects. Circulation 1999, 99:2219c-2222c.
20. Esposito K., Pontillo A., Ciotola M., et al. Weight loss reduces IL-18 levels in obese women. J Clin Endocrinol Metab 2002, 87:3864-3866.
21. Mohamed-Ali V., Goodrick S., Rawesh A., et al. Subcutaneous adipose tissue releases IL-6 but not tumor necrosis factor-alpha in vivo. J Clin Endocrinol Metab 1997, 82:4196-4200.
22. Lau D., Yan H., Abdel-Hafez M., Kermouni A. Adipokines and the paracrine control of their production in obesity and diabetes. Int J Obes Relat Metab Disord 2002, 26:S111. (abstract).
23. Rotter V., Nagaev I., Smith U. Interleukin-6 induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects. J Biol Chem 2003, 278:45777-45784.
24. Escobar-Morreale H.F., Botella-carrettero J.L., Villuendas G., Sancho J., San Millan J.L. Serum IL-18 concentrations are increased in the polycystic ovary syndrome: relationship to insulin resistance and to obesità. J Clin Endocrinol Metab 2004, 89:806-811.
25. Nikolajuk A., Kowalska I., Karczewska-Kupczewska M., et al. Serum soluble glycoprotein 130 concentration is inversely related to insulin sensitivity in women with polycystic ovary syndrome. Diabetes 2010, 50:1026-1029.
26. Febbraio M.A. gp130 receptor ligands as potential therapeutic targets for obesity. J Clin Invest 2007, 117:841-849.
27. Carey A.L., Febbraio M.A. Interleukin-6 and insulin sensitivity: friend or foe?. Diabetologia 2004, 47:1135-1142.
28. Atreya R., Mudter J., Finotto S., et al. Blokade of interleukin 6 trans-signalling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo. Nat Med 2000, 6:583-588.
29. Bonora E., Targher G., Alberiche M., et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000, 23:57-63.